Candel Therapeutics, Inc. (CADL)

USD 6.53

(-1.06%)

Market Cap (In USD)

277.36 Million

Revenue (In USD)

-

Net Income (In USD)

-37.93 Million

Avg. Volume

364.83 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.06-14.6
PE
-
EPS
-
Beta Value
-0.874
ISIN
US1374041093
CUSIP
137404109
CIK
1841387
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Employee Count
-
Website
https://www.candeltx.com
Ipo Date
2021-07-27
Details
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.